Pershing Square Pushes Poll For Allergan Shareholders

May 14 2014 | 12:16pm ET

Pershing Square Capital Management is looking to its fellow Allergan Inc. shareholders to pressure the Botox-maker to negotiate with Valeant Pharmaceuticals International, whose $46 billion takeover offer it rejected on Monday.

The New York-based hedge fund yesterday disclosed that it demanded a list of registered shareholders from Allergan, with plans to hold a referendum on whether the company should speak with potential buyers. Pershing Square chief William Ackman told The Wall Street Journal that the non-binding poll would give “shareholders an opportunity to express their point of view. What could be more democratic than that?”

The unusual maneuver, taken instead of seeking to force a special meeting, helps Pershing Square sidestep Allergan’s poison pill, which not only blocks the hedge fund from increasing its 9.7% stake, but also limits its communications with shareholders. Proxy campaigns are excluded from the restrictions.

The referendum also keeps Pershing Square in control of the process; if a special meeting were called, Allergan would have up to four months to schedule it.

Allergan, which called Valeant’s Pershing Square-backed offer too low, and which said it prefers to remain independent, said that the referendum was a “self-serving enterprise” that allows Valeant and the hedge fund to dictate “their own process.”

Valeant also made clear that it wasn’t giving up, saying it would improve its cash-and-stock offer on May 28. It is unclear whether the company will make a higher offer or increase the amount of cash in the deal, in an effort to entice Allergan to the negotiating table.


In Depth

Kettera Q&A: The Advantages of Alternative Investment Platforms

Oct 28 2016 | 5:52pm ET

The past several years have seen a distinct push towards easier and cheaper access...

Lifestyle

Midtown's Plaza District Fades As Manhattan Office Landscape Shifts

Nov 22 2016 | 6:32pm ET

Lower leasing costs, more efficient office space and the hope of projecting an image...

Guest Contributor

Nowhere to Hide: Why the Future of Asset Management Depends on Innovation

Nov 15 2016 | 6:55pm ET

Information technology has reshaped the asset management industry’s periphery,...

 

From the current issue of

Chicago-based independent futures brokerage and clearing firm R.J. O’Brien & Associates (RJO) has hired industry veteran Daniel Staniford as Executive Director, responsible for the firm’s institutional business development in New York and London.

AVAILABLE NOW at BARNES & NOBLE

NEWSTAND LOCATOR